News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celsion Corporation (CLN) to Present at Upcoming Investor Conferences in September



8/30/2012 9:19:22 AM

LAWRENCEVILLE, NJ--(Marketwire - August 30, 2012) - Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that Michael H. Tardugno, Celsion's President and Chief Executive Officer, will be presenting at the following upcoming investor conferences during the month of September.

Conference: Stifel Nicolaus 2012 Healthcare Conference
Date: Thursday, September 6, 2012 at 9:10 a.m. Eastern Time in Boston, MA

Conference: Rodman & Renshaw Annual Global Investment Conference
Date: Monday, September 10, 2012 at 10:50 a.m. Eastern Time in New York, NY

A live webcast of the presentations will be available on Celsion's website at http://investor.celsion.com/events.cfm. The webcast will be archived on the same site for replay following the conference.

About Celsion Corporation

Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license, or commercialization agreements with leading institutions including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital and the Beijing Cancer Hospital. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; FDA and regulatory risks; the need to raise funds for planned drug development; the Company's history of losses and its expectation of continuing to incur such losses; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


Investor Contact
David Pitts
Argot Partners
212-600-1902
Email Contact


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES